 AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia (HPP), a rare metabolic bone disorder. The global programme included two placebo-controlled, randomised trials and one active-controlled, open-label, randomised paediatric switch trial. 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. | 
